iNeo-Vac-P01Zhejiang Provincial People’s Hospitalpancreatic ductal adenocarcinoma (PDAC)
…s Hospital, enrolled PDAC patients who initiated treatment with iNeo-Vac-P01 following completion of standard adjuvant chemotherapy. The vac…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 961–1,020 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
mineralocorticoid receptor antagonist4mycophenolic acid4opioid medications4paroxetine4polyethylene glycol4prednisone-equivalent4quinolones4tenofovir disoproxil fumarate4thyroxine4topical steroids4SACT3Suvorexant3hrHPV3mFOLFIRINOX3Sitravatinib3S-13CGRP3Phentermine3Phe3Enpatoran3UACR3Obesity medications3DZP3ANI3BA3ACP3AB5983DXM3MDI3TK-63023IMA2033MRX3PDS01ADC3UPA303AKK3UPA153Vastrax3hs-CRP3177Lu-PSMA3DMPA-SC3Delamanid3OBZ3Oestradiol3Zilucoplan3DeepSeek-R13Depemokimab3FIB43HX1113Succinate32-Chloroprocaine3ARB3Cr(VI)3Cystatin C3Fisetin3PIM3SZC3Dalbavancin3KSQ-004EX3LTX-3153Migalastat3
Articles mentioning drugs
10,506 articles · page 305 of 876nab-paclitaxeltoripalimabDNV3cisplatinadvanced melanomaunresectable/metastatic melanomachemotherapymucosal melanoma
…g DNV3 (anti-LAG-3), toripalimab (anti-PD-1), and chemotherapy (nab-paclitaxel/cisplatin) in 27 Asian patients with unresectable/metastatic me…
bevacizumab-bvzrRecurrent respiratory papillomatosis (RRP)NIH IRBcolorectal cancer
… infection and papilloma regrowth that occurs upon cessation of bevacizumab-bvzr.Trial Registration This trial was registered on clinicaltrials.…
fludarabinecyclophosphamideLMY-920lymphomamyelomaCase Comprehensive Cancer Centersystemic lupus erythematosusMMDLBCLCLL+1 more
… using the BAFF-CAR transposon construct. Patients then receive fludarabine (30 mg/m 2/d) and cyclophosphamide (500 mg/m2/d) lymphodepletio…
CT-95MSLNmesotheliomacolorectal cancercolorectal cancersNCT06756035non-small cell lungnon-small cell lung cancersolid tumorsplatinum resistant ovarian cancer
…els are single patient cohorts (0.1 µg/kg starting MABEL dose). CT-95 is delivered as weekly IV infusions, with steroid premedication…
FTY720Flt3LDoxil D1TNBCNCT05029999Triplet therapyanthracycline chemotherapy
…ansion of T cells. Notably, blockade of lymphocyte egress using FTY720 did not compromise therapeutic efficacy, suggesting that pre-ex…
95.0%
BNT162b2anti-PD-L1 therapy
…nity against pathogen antigens via mRNA-based vaccines, such as BNT162b2, significantly enhances cancer immunotherapy efficacy. Given wi…
lenvatinibsorafenibatezolizumab-bevacizumabpembrolizumabProton-TKIProton radiotherapyLinkou Chang Gung Memorial Hospitalhepatocellular carcinomaHCCProton-TKI
…mbrolizumab (n = 5). Tyrosine kinase inhibitors (TKIs) included lenvatinib (n = 16) and sorafenib (n = 13).Results With a median follow-up…
PlinabulinNSCLCRCCSCCHNICB-relapsed/refractory cancersfibrolamellar HCCParse Biosciences
…o-tumor macrophages.Reference Lin S, Subbiah V, Cohen E, et al. Plinabulin following radiation enhances dendritic cell maturation and chec…
RAS inhibitorsRASisolid tumorsMoffitt Cancer CenterLUADPDACmelanoma
…map for rational design of combination therapies that synergize RAS inhibitors with precision immunotherapies—advancing the goal of durable tu…
rituximab-analogrituximabcancerautoimmune diseases
…use, IV, single dose, short-term), G3 (vehicle, long-term), G4 (rituximab-analog, 20µg/mouse, IV, single dose, long-term). G1/G2: Peripheral blo…
pembrolizumabVLPONC-01head and neck squamous cell carcinoma (HNSCC)HNSCC
…umor response for either VLPONC-01 alone or in combination with pembrolizumab treatment.Trial Registration NCT06736379Abstract 711 Figure 1Al…